Press Releases

Pulmatrix Activates Sites for Pulmazole Phase 2 Clinical Study

LEXINGTON, Mass., July 9, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) announces today that three sites in the United States have been activated for the Phase 2 clinical investigation for Pulmazole (PUR1900) – an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.  The three activated sites are able to recruit, screen and enroll patients.  

Pulmatrix logo (PRNewsFoto/Pulmatrix, Inc.)

The study has regulatory approval in the United States, United Kingdom and Australia which account for 17 of the study's 25 treatment sites.  Pulmatrix is pursuing regulatory approval for the in India and Poland, which will account for the remaining 8 treatment sites.

"We are excited to announce the initiation of our Phase 2 Pulmazole trial," said Ted Raad, Pulmatrix's chief executive officer.  "With our Clinical Advisory Board of ABPA experts, we developed a meaningful clinical trial that will help inform the treatment of this debilitating disease and further advance the Pulmazole program."

The Phase 2 study is a global, multicenter, 4 arm trial.  Enrolled subjects will be randomly assigned (1:1:1:1) into 4 arms of 16 subjects each (n=64 total) and will receive 10 mg, 20 mg, or 35 mg of PUR1900 or placebo, administered via once daily dry powder inhalation daily for 28 days.  The primary objective of the study is to evaluate the safety and tolerability of multiple-dose administration of Pulmazole given to adult asthmatic subjects with ABPA.  Secondary objectives include characterizing the pharmacokinetics of multiple dose administration of inhaled PUR1900 in plasma and sputum, as well as evaluating the effect of Pulmazole on relevant biomarkers of inflammation, pulmonary function (FEV1), asthma symptoms, and aspergillus burden in sputum.  Top line data is expected in mid 2020.

About Pulmatrix  
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases including asthma and chronic obstructive pulmonary disease ("COPD"). Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements of historical fact, and may be identified by words such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that", "may," "plans," "seeks," "projects," "targets," and "would," and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to,  the ability to enroll patients in planned clinical trials, delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the SEC, including its annual report on Form 10-K filed with the Securities and Exchange Commission on February 19, 2019, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact         

Ted Raad, CEO             

William Duke, CFO          

(781) 357-2350      

(781) 357-2333


SOURCE Pulmatrix, Inc.